EFUAF

CASE QA0239A CIP

## **CERTIFICATE OF MAILING**

Leereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313.

Anastasia P. Winslow

Type or print name

Signature:

September \$\lambde{\bmu} 2004

Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

MORIARTY ET AL.

Examiner: V. Balasubramanian

**APPLICATION NO: 09/891,750** 

FILED: JUNE 26, 2001

FOR: N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION

Assistant Commissioner for Patents

Washington, D.C. 20231

## DECLARATION OF KATERINA LEFTHERIS

- I, Katerina Leftheris, do hereby declare as follows:
- 1. I am employed with Bristol-Myers Squibb Company, the assignee of this patent application, and I am an inventor in the above-referenced patent application.
- 2. Below is a table showing activity data detected for inhibition of the p38 kinase for a representative compound as claimed in the present patent application, wherein the right-hand phenyl ring has a para substituent (row 1), as compared with a meta substituent (row 2).

TABLE 1

Compound	Z	R <sub>11</sub>	P38 inhibitory activity – IC <sub>50</sub>
H <sub>3</sub> C H <sub>3</sub> C H <sub>3</sub> C NH <sub>2</sub> NH <sub>2</sub> NH <sub>2</sub>	H <sub>3</sub> C N N N N N N N N N N N N N N N N N N N	NH NH	1360 nM
NH2  Amide is positioned para, not meta  H <sub>3</sub> C  NH2  Amide is positioned para, not meta	H <sub>3</sub> C N L	N NH	> 20,000 nM

3. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Executed this 15 day of September, 2004.

Katerina Leftheris